Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Gefitinib in Advanced EGFR+ Non-squamous NSCLC
NCT03602027Phase 1Unknown
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Aug 2018
- Primary completion
- Dec 2018
01
Overview
Phase 1, open-label trial of anlotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by The Second Affiliated Hospital of Nanchang University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03602027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602027.